BMS-986419 for Healthy Subjects
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of BMS-986419 (Part 1) and the effects of multiple doses of BMS-986419 on cardiac repolarization (Part 2) in healthy participants.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, since the study is for healthy participants, it's likely that you should not be on any regular medications. Please check with the study team for specific guidance.
What safety data exists for BMS-986419 in humans?
There is no specific safety data available for BMS-986419, but similar compounds like BMS-986001 and BMS-378806 have been studied. BMS-986001 was generally safe and well tolerated in healthy subjects, while BMS-378806 was also safe over a range of doses. However, BMS-986094, another related compound, was withdrawn due to unexpected heart and kidney issues in animal studies.12345
Who Is on the Research Team?
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Are You a Good Fit for This Trial?
This trial is for healthy individuals with a BMI between 18.0 and 30.0 kg/m^2. They must pass medical history reviews, physical exams, vital sign checks, ECGs, and lab tests to confirm their health status.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment Part 1
Participants receive BMS-986419 or placebo to assess safety, tolerability, and pharmacokinetics
Treatment Part 2
Participants receive multiple doses of BMS-986419 to evaluate effects on cardiac repolarization
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- BMS-986419
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania